Summary:
In patients with type 2 diabetes (T2D) and heart failure with preserved ejection fraction (HFpEF),
dapagliflozin significantly reduced myocardial fibrosis and improved cardiac structure, metabolic control, and exercise tolerance compared to control group therapies, though it was associated with mild and tolerable adverse effects, including urinary tract infections.
| PICO | Description |
|---|---|
| Population | Patients with heart failure with preserved ejection fraction (HFpEF) and co-existing type 2 diabetes mellitus (T2D). |
| Intervention | Dapagliflozin (SGLT2 inhibitor) therapy. |
| Comparison | Standard treatment for HFpEF without SGLT2 inhibitors. |
| Outcome | Dapagliflozin significantly reduced myocardial fibrosis, improved cardiac structural parameters, enhanced metabolic control, and increased exercise capacity. Adverse effects included mild urinary tract infections, which were manageable in most cases. |
Source: Arif Albulushi, et al. “Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study.” PubMed. Read article here.
